Strategic leader driving business growth through expert business development and alliance management, with a proven track record of expanding market access and building impactful patient support initiatives. Skilled in executing government tenders while navigating complex regulatory environments to deliver compliant, practical solutions. Adept at transforming challenges into sustainable opportunities, ensuring strong governance and operational excellence. Committed to fostering long-term partnerships that support organizational success and growth.
Overview
21
21
years of professional experience
1
1
Certification
Work History
Institutional Business & Alliance Management Manager
Takeda Healthcare Philippines, Inc.
06.2025 - Current
Access-to-Medicines projects recognized in Takeda’s 2025 Access to Medicines Report (Patient Navigator Program with 300 px supported with Guarantee Letters; partnerships with funding sources).
Delivered 34% year-over-year growth through strategic account negotiations and monthly commitment plans.
Recognized as a “Values Ambassador” (ISEA Chronicles) for commitment to ethical standards and corporate values.
Captured 25% market share by building and sustaining alliances with hospitals, payors, and stakeholders to expand access.
Managed 99% service levels across trade partners: improved operational execution through clear Statements of Work and Master Services Agreements.
Led internal and external discussions on MAIFIP funding opportunities to support patient access initiatives.
Enabled 100% fulfillment of tenders and emergency requirements for Factor VIII inhibitor by initiating monthly coordination with Zuellig’s government accounts team and Market Access.
Rolled out a Finished Goods traceability sample-testing project (Q2; first in Southeast Asia), strengthening patient safety and organizational risk control.
Associate Manager, Institutional Business & Alliance Management
Takeda Healthcare Philippines, Inc.
02.2023 - 05.2025
Recognized as “Perseverance Leader” (Oct 2024) for exceptional dedication and resilience.
Launched the Patient Navigator Program with a private partner, enhancing access to government/private funding and contributing ~30% of Takeda business.
Surpassed business plan targets by 168%, driving sustainable growth for Oncology and Rare Diseases brands.
Negotiated and secured an MOU with a top-tier private institution, improving medication access and care for Cancer and IBD patients.
Forged partnerships with private payors, improving market performance of Oncology and Rare Disease brands.
Recognized as Best in KAM class; delivered 30% year-over-year Key Account growth.
Spearheaded Adcetris Redesign Program implementation, achieving 214% growth versus commitment.
Launched Low Remaining Shelf-Life Program, averting a potential ₱1M write-off.
Optimized Ninlaro Access Program, reducing patient access time from 3 days to 1 day.
Introduced Guarantee Letters to streamline the Patient Assistance Program (PAP).
Expanded sub-distribution channels (2 to 5), improving patient access to essential medications.
Delivered launch excellence by introducing two products within six months, ensuring trade availability ahead of launch.
Product Specialist & Institutional Accounts
Johnson & Johnson (Immunology)
01.2022 - 12.2023
Drove customer engagements in inflammatory bowel disease; developed 10 key opinion leaders and delivered 281% territory growth vs. prior year.
Executed promotional programs (national/regional/institutional) showcasing patient-focused, multidisciplinary care approaches.
Activated 5 international HMOs and public funding agencies (e.g., DSWD, DOH MAIP) supporting ~25% of total business share.
Special assignment OIC: coordinated with customer service to support HCP ordering and patient access program enrollment facilitation.